ASX ANNOUNCEMENT

INVION RECEIVES >$0.5M R&D TAX INCENTIVE REBATE

MELBOURNE (AUSTRALIA) 19 November 2026: Invion Limited (ASX: IVX) ("**Invion**" or the "**Company**"), a clinical-stage life sciences company developing its next-generation photodynamic therapy platform (**NGPDT**) called Photosoft™, is pleased to advise that it has received net proceeds of $502,675 (cash refund) under the Australian Government's Research and Development (**R&D**) Tax Incentive program for FY26.

The refund relates to eligible research and development expenditure undertaken by Invion in Australia and provides non-dilutive funding to support the Company's ongoing development activities.

Invion's research and development efforts are focused on advancing its proprietary Photosoft™ platform technology and lead cancer drug candidate INV043, which is being evaluated across multiple indications.

The R&D Tax Incentive is a key component of Invion's funding strategy, complementing other sources of capital available to the Company to support its clinical pipeline, which includes the planned Ph II skin cancer trial and anogenital trial that is co-sponsored by the Peter MacCallum Cancer Centre. Invion recently announced two complementary financing arrangements designed to cover up to ~85% of future clinical trial costs.

This announcement was approved for release by Invion's Board of Directors.

***Sign up at Invion's Investor Hub to receive regular updates, provide feedback and participate in discussions**: https://investors.inviongroup.com/*

Investor and Media enquiries:

Thian Chew (Chairman & CEO)
T: +61 3 9692 7222
E: investor@inviongroup.com

Brendon Lau (Investor & Media Relations)
M: +61 409 341 613
E: brendon.lau@inviongroup.com

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on Invion's beliefs, assumptions, and expectations and on information currently available to Invion.

All statements that address operating performance, events, funding or developments that Invion or its directors expect or anticipate will occur in the future are forward-looking statements, including, without limitation, statements as to the expectations of Invion or the market it operates in.

Invion believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Invion does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. No assurance or guarantee is, or should be taken to be, given in relation to, and no reliance should be placed on, the future business performance or results of Invion or the likelihood that the current assumptions, estimates or outcomes will be achieved. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

About Invion

Invion is a life-science company that is leading the global research and development of the Photosoft™ technology for the treatment of a range of cancers, ophthalmic and infectious diseases. Invion holds the global exclusive license to the Photosoft technology for multiple cancer and non-cancer disease indications. Invion is listed on the ASX (ASX: IVX). Find out more at www.Inviongroup.com.

About Next Generation Photodynamic Therapy (NGPDT)

Invion is developing its Photosoft™ platform technology as a novel Next Generation Photodynamic Therapy (NGPDT). NGPDT uses non-toxic photosensitisers and light to selectively kill cancer cells and promote an anti-cancer immune response. Less invasive than surgery and with minimal side effects, NGPDT offers an alternative treatment option aimed at achieving complete tumour regression and long-lasting remission. NGPDT has also demonstrated potential in ophthalmic applications, as well as broad-spectrum antimicrobial activity across multiple bacteria, fungi and viruses.